Dr. Abbas Shahmohammadi is the director of the UF Thoracic and Lung Transplant/ECMO Intensive Care Unit. He specializes in pulmonary disease and critical care medicine. His clinical interests are in acute respiratory distress syndrome (ARDS), extracorporeal membrane oxygenation (ECMO), lung transplantation and pulmonary arterial hypertension (PAH).
Areas of Expertise (5)
Advanced Lung Failure
Media Appearances (5)
250 days and counting: Waiting on new lungs after Covid
NBC News online
While most Americans are shedding their masks and returning to their pre-pandemic lives, Marie Jackson remains in a Chicago hospital room. She has been there for more than 250 days. There is no indication yet when Jackson, 53, will be able to go home. She's waiting on a new pair of lungs; hers were irreversibly scarred when she was sickened by Covid-19 last July.
Active duty marine released from hospital after long battle with COVID-19
CBS 4 News online
After spending 5 months hospitalized at UF Health Shands Hospital, Robert Domen was able to walk out of the hospital. “I will live everyday forever grateful, thank-you," he said. Domen was greeted by Marines, family, friends and staff cheering him on, waving American flags, as he walked down the hall. Domen is an active duty Marine, who’s served for more than 30 years, and he attributes his triumphant battle with COVID to everything he learned in the military.
Devine Intervention: Stars Align for Pulmonologist’s Lung Transplant
UF Health online
After night shifts in the ICU, Sean Devine is tired. This is not atypical. In fact, Sean and his family have grown to expect it. When he is on nights, the critical care pulmonologist arrives home weary in the early dawn.
International research outlines early outcomes on lung transplantation for severe COVID-19
UF Health online
The UF Health lung transplant team has collaborated with researchers around the world to identify preliminary guidelines for successful transplantation in patients whose lungs have been permanently damaged by the SARS-CoV-2 virus. In a landmark study published online March 31 in The Lancet Respiratory Medicine, members of the lung transplant program at UF Health, the University of Florida’s academic health center, describe an analysis of early findings from patients who received lung transplants after COVID-19 damaged their lungs beyond repair.
COVID-19 double lung transplant survivor gets second shot at life: “A life changing event”
WCJB 20 ABC online
After more than 10 years working as a security officer at UF Health, 55-year-old Kenneth Traylor never pictured being on the other side of the hospital walls. Kenneth was an active, fit father of 10 children who spent his extra time strength coaching students in Alachua County. That was until he started feeling COVID-19 symptoms and checked into the hospital last October. His wife, Wanda Traylor, said what began with him feeling tired, quickly turned into months of lying in a hospital bed.
Incidence, risk factors, and sequelae of dysphagia mediated aspiration following lung transplantationThe Journal of Heart and Lung Transplantation
Justine Dallal-York, et. al
We aimed to determine dysphagia profiles before and after lung transplantation (prevalence, incidence) and to examine predictors and health-related outcomes of aspiration in individuals undergoing lung transplantation. A retrospective single-center study of consecutive adults undergoing lung transplantation and completing a postoperative videofluoroscopic swallowing study between 2017 and 2020 was conducted.
Early outcomes after lung transplantation for severe COVID-19: a series of the first consecutive cases from four countriesThe Lancet Respiratory Medicine
Ankit Bharat, et. al
Lung transplantation is a life-saving treatment for patients with end-stage lung disease; however, it is infrequently considered for patients with acute respiratory distress syndrome (ARDS) attributable to infectious causes. We aimed to describe the course of disease and early post-transplantation outcomes in critically ill patients with COVID-19 who failed to show lung recovery despite optimal medical management and were deemed to be at imminent risk of dying due to pulmonary complications.
Intravenous Alpha-1 Antitrypsin Therapy for Alpha-1 Antitrypsin Deficiency: The Current State of the EvidenceChronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
Mark L. Brantly, et. al
Alpha-1 antitrypsin deficiency (AATD) is a largely monogenetic disorder associated with a high risk for the development of chronic obstructive pulmonary disease (COPD) and cirrhosis. Intravenous alpha-1 antitrypsin (AAT) therapy has been available for the treatment of individuals with AATD and COPD since the late 1980s. Initial Food and Drug Administration (FDA) approval was granted based on biochemical efficacy.